Cargando…

Influence of Antiplatelet Agents on the Lipid Composition of Platelet Plasma Membrane: A Lipidomics Approach with Ticagrelor and Its Active Metabolite

Lipids contained in the plasma membrane of platelets play an important role in platelet function. Modifications in the lipid composition can fluidify or rigidify the environment around embedded receptors, in order to facilitate the access of the receptor by the drug. However, data concerning the lip...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lagoutte-Renosi, Jennifer, Allemand, Florentin, Ramseyer, Christophe, Rabani, Vahideh, Davani, Siamak
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866994/ https://www.ncbi.nlm.nih.gov/pubmed/33572690 http://dx.doi.org/10.3390/ijms22031432

Ejemplares similares

Validation of an HPLC–MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice
por: Lagoutte-Renosi, Jennifer, et al.
Publicado: (2021)

Cholesterol-Rich Microdomains Contribute to PAR1 Signaling in Platelets Despite a Weak Localization of the Receptor in These Microdomains
por: Rabani, Vahideh, et al.
Publicado: (2020)

Proteomics and Lipidomics of Black Soldier Fly (Diptera: Stratiomyidae) and Blow Fly (Diptera: Calliphoridae) Larvae
por: Rabani, Vahideh, et al.
Publicado: (2019)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
por: Marczewski, Margaret M, et al.
Publicado: (2010)

Membrane Environment Modulates Ligand-Binding Propensity of P2Y12 Receptor
por: Haghighi, Fatemeh, et al.
Publicado: (2021)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Systemic Design and Evaluation of Ticagrelor-Loaded Nanostructured Lipid Carriers for Enhancing Bioavailability and Antiplatelet Activity
por: Son, Gi-Ho, et al.
Publicado: (2019)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

Ticagrelor as an Alternative Antiplatelet Therapy in Cardiac Patients Non-Sensitive to Aspirin
por: Khan, Hamzah, et al.
Publicado: (2020)

Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles
por: Giacomazzi, Alice, et al.
Publicado: (2016)

Platelet-Mimicking Nanosponges for Functional Reversal of Antiplatelet Agents
por: Xu, Junchao, et al.
Publicado: (2023)

The effect of antiplatelet drug on coronary endothelial and microvascular function: comparison with ticagrelor and clopidogrel
por: Choi, Woong Gil, et al.
Publicado: (2021)

Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial
por: Li, Pan, et al.
Publicado: (2016)

Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
por: Davis, Estella M, et al.
Publicado: (2013)

Spontaneous subdural hematoma and antiplatelet therapy: Does efficacy of Ticagrelor come with added risk?
por: Suryanarayana Sharma, Pattanagere Manjunatha, et al.
Publicado: (2015)

Platelet-Derived Extracellular Vesicles as Target of Antiplatelet Agents. What Is the Evidence?
por: Taus, Francesco, et al.
Publicado: (2019)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Walking the Line with Ticagrelor: Meta-Analysis Comparing the Safety and Efficacy of Ticagrelor Monotherapy after a Short Course of Ticagrelor-Based Dual Antiplatelet Therapy versus Standard Therapy in Complex Percutaneous Coronary Intervention
por: Condello, Francesco, et al.
Publicado: (2021)

Lipidomics Profiles and Lipid Metabolite Biomarkers in Serum of Coal Workers’ Pneumoconiosis
por: Chen, Zhangjian, et al.
Publicado: (2022)

Ticagrelor – toward more efficient platelet inhibition and beyond
por: Kubisa, Michał J, et al.
Publicado: (2018)

Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial
por: Johnson, Thomas W., et al.
Publicado: (2020)

Risk of Major Bleeding With Potent Antiplatelet Agents After an Acute Coronary Event: A Comparison of Ticagrelor and Clopidogrel in 5116 Consecutive Patients in Clinical Practice
por: Mullen, Liam, et al.
Publicado: (2021)

Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction
por: Yeh, Jong-Shiuan, et al.
Publicado: (2023)

Pharmacokinetic Modeling of Morphine’s Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers
por: Buszko, Katarzyna, et al.
Publicado: (2021)

Cost-effectiveness of Platelet Function-Guided Strategy with Clopidogrel or Ticagrelor
por: Lomakin, Nikita, et al.
Publicado: (2019)

Temporal Variability of Platelet Reactivity in Patients Treated with Clopidogrel or Ticagrelor
por: Yun, Kyeong Ho, et al.
Publicado: (2019)

Comparison of ticagrelor and clopidogrel on platelet function and prognosis in unstable angina
por: Li, Chun, et al.
Publicado: (2022)

Antiplatelet Agents Can Promote Two-Peaked Thrombin Generation in Platelet Rich Plasma: Mechanism and Possible Applications
por: Tarandovskiy, Ivan D., et al.
Publicado: (2013)

A Remote Assay for Measuring Canine Platelet Activation and the Inhibitory Effects of Antiplatelet Agents
por: Dunning, M., et al.
Publicado: (2017)

Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria
por: Hannachi, Nadji, et al.
Publicado: (2020)

Independent association of Lp(a) with platelet reactivity in subjects without statins or antiplatelet agents
por: Liu, Huixing, et al.
Publicado: (2022)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
por: Wang, Shuai, et al.
Publicado: (2022)

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome
por: Abergel, Eitan, et al.
Publicado: (2010)

Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor
por: Na, Young-Guk, et al.
Publicado: (2019)

Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in ST‐segment elevation myocardial infarction
por: Welsh, Robert C., et al.
Publicado: (2021)

Platelets: Pathophysiology and Antiplatelet Drug Therapy
por: Snyder, Edward L.
Publicado: (1983)

A lipid metabolite lipidomics assay for prediction and severity evaluation of rotator cuff injury
por: Huang, Hongjie, et al.
Publicado: (2022)

Effect of antiplatelet agents and tyrosine kinase inhibitors on oxLDL-mediated procoagulant platelet activity
por: Zheng, Tony J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vn4mt283ls65n5ahktafthtq52